The approach could enable 30-minute testing for a heart condition that is newly treatable following recent drug approvals.

Owner Zishan Alvi submitted claims for COVID-19 tests that were either never performed or were performed incorrectly, releasing potentially false negative test results to patients.

NEW YORK – Qiagen announced on Wednesday that it has launched a third-party partnering program for its clinical digital PCR platform and signed an agreement with the program's inaugural partner, South ...

Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.

Adding the firm's multi-cancer early detection test to standard-of-care screening demonstrated substantially greater additional cancer detection than in Pathfinder.

The company uses artificial intelligence to detect metabolic patterns from urine samples that indicate prostate cancer.

NEW YORK – In a letter to customers on Wednesday, Bio-Rad Laboratories announced that it has decided against implementing a tariff surcharge that the company on May 21 said it was considering for at ...

Caris plans to use the proceeds from its IPO to pay off about $400 million worth of debt, he noted, and it also intends to use the funds to drive toward profitability next year and continue expanding ...

The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.